Compare HTZ & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | FDMT |
|---|---|---|
| Founded | 1918 | 2013 |
| Country | United States | United States |
| Employees | 26000 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.4M | 695.3M |
| IPO Year | N/A | 2019 |
| Metric | HTZ | FDMT |
|---|---|---|
| Price | $1.81 | $10.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.67 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 26.8M | 868.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $3.62 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.71 | $4.27 |
| 52 Week High | $8.18 | $14.00 |
| Indicator | HTZ | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 24.98 | 40.73 |
| Support Level | N/A | $9.71 |
| Resistance Level | $5.42 | $10.50 |
| Average True Range (ATR) | 0.16 | 0.79 |
| MACD | 0.10 | -0.30 |
| Stochastic Oscillator | 20.93 | 9.04 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).